All In Biotech

NDA 021303 · Takeda Pharms USA

Adderall Xr 10

Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · Oral

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Oct 11, 2001

Approved uses

3

Original approval plus efficacy supplements

Registered trials

5

3 Phase 3, 0 recruiting

FAERS reports

41,907

18,198 serious, 515 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, and ADDICTION ADDERALL XR ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ADDERALL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE,...

What it is approved for

From the label in effect Apr 30, 2026.

ADDERALL XR, a CNS stimulant, is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. ( 1 ) Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. ( 5.5 , 8.4 ) 1.1 Attention Deficit Hyperactivity Disorder ADDERALL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.4 )].

Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • ADDERALL XR 10 · AMPHETAMINE ASPARTATE 2.5MG; AMPHETAMINE SULFATE 2.5MG; DEXTROAMPHETAMINE SACCHARATE 2.5MG; DEXTROAMPHETAMINE SULFATE 2.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • ADDERALL XR 15 · AMPHETAMINE ASPARTATE 3.75MG; AMPHETAMINE SULFATE 3.75MG; DEXTROAMPHETAMINE SACCHARATE 3.75MG; DEXTROAMPHETAMINE SULFATE 3.75MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • ADDERALL XR 25 · AMPHETAMINE ASPARTATE 6.25MG; AMPHETAMINE SULFATE 6.25MG; DEXTROAMPHETAMINE SACCHARATE 6.25MG; DEXTROAMPHETAMINE SULFATE 6.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • ADDERALL XR 20 · AMPHETAMINE ASPARTATE 5MG; AMPHETAMINE SULFATE 5MG; DEXTROAMPHETAMINE SACCHARATE 5MG; DEXTROAMPHETAMINE SULFATE 5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • ADDERALL XR 5 · AMPHETAMINE ASPARTATE 1.25MG; AMPHETAMINE SULFATE 1.25MG; DEXTROAMPHETAMINE SACCHARATE 1.25MG; DEXTROAMPHETAMINE SULFATE 1.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • ADDERALL XR 30 · AMPHETAMINE ASPARTATE 7.5MG; AMPHETAMINE SULFATE 7.5MG; DEXTROAMPHETAMINE SACCHARATE 7.5MG; DEXTROAMPHETAMINE SULFATE 7.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Amphetamine Aspartate" as an intervention, any sponsor and status, largest first.

All 5 trials
  • ShireTakeda (TAK)

    NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00152022 · 412 participants · Start Apr 25, 2005 · Primary completion Nov 4, 2005

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00150579 · 240 participants · Start Jan 27, 2005 · Primary completion Jun 14, 2005

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity

  • ShireTakeda (TAK)

    NCT00202605 · 72 participants · Start Sep 29, 2005 · Primary completion Jan 6, 2006

    Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity

    Sites: Little Rock, Arkansas; Irvine, California; Las Vegas, Nevada · 4 sites in all

  • ShireTakeda (TAK)

    NCT03327402 · 24 participants · Start Mar 13, 2018 · Primary completion Oct 5, 2018

    Drug: SHP465 · For: Attention Deficit Hyperactivity Disorder (ADHD)

    Sites: Little Rock, Arkansas; Orlando, Florida; Evansville, Indiana · 8 sites in all

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,838
  • fatigue3,271
  • nausea2,969
  • headache2,700
  • anxiety2,546
  • depression2,150
  • feeling abnormal2,034
  • pain1,805
  • dizziness1,792
  • somnolence1,743
  • insomnia1,642
  • off label use1,517

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200436
200538
200725
20085
20097
201025
201163
2012374
2013892
20141,261
20153,395
20167,276
20173,081
20183,384
20193,220
20202,918
20212,302
20222,889
20233,054
20242,862
20252,860
20261,940

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Takeda · Also marketed as Adderall Xr 15, Adderall Xr 25, Adderall Xr 20, Adderall Xr 5, Adderall Xr 30

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.